| Literature DB >> 30294960 |
Linda Quatrini1, Eric Vivier1,2,3, Sophie Ugolini1.
Abstract
The activities of the immune system in repairing tissue injury and combating pathogens were long thought to be independent of the nervous system. However, a major regulatory role of immunomodulatory molecules released locally or systemically by the neuroendocrine system has recently emerged. A number of observations and discoveries support indeed the notion of the nervous system as an immunoregulatory system involved in immune responses. Innate lymphoid cells (ILCs), including natural killer (NK) cells and tissue-resident ILCs, form a family of effector cells present in organs and mucosal barriers. ILCs are involved in the maintenance of tissue integrity and homeostasis. They can also secrete effector cytokines rapidly, and this ability enables them to play early roles in the immune response. ILCs are activated by multiple pathways including epithelial and myeloid cell-derived cytokines. Their functions are also regulated by mediators produced by the nervous system. In particular, the peripheral nervous system, through neurotransmitters and neuropeptides, works in parallel with the hypothalamic-pituitary-adrenal and gonadal axis to modulate inflammatory events and maintain homeostasis. We summarize here recent findings concerning the regulation of ILC activities by neuroendocrine mediators in homeostatic and inflammatory conditions.Entities:
Keywords: barrier defense; hormones; innate lymphoid cells; natural killer (NK) cells; neuroimmunology; neuropeptides
Mesh:
Substances:
Year: 2018 PMID: 30294960 PMCID: PMC6221181 DOI: 10.1111/imr.12707
Source DB: PubMed Journal: Immunol Rev ISSN: 0105-2896 Impact factor: 12.988
Figure 1Glucocorticoids regulate NK cells and ILC1s functions upon MCMV infection. MCMV infection induces the activation of the HPA axis: the hypothalamus produces the corticotropin‐releasing hormone (CHR), which activates the pituitary gland to release the adrenocorticotropin hormone (ACTH) which, finally, induces the secretion of glucocorticoids (GCs) into the bloodstream by the adrenal gland. Signaling transduced by different combinations of cytokines and other unidentified potential mediators in the spleen and liver microenvironment differentially cooperates with the glucocorticoid receptor (GR) to regulate transcription. As a result, the control of gene expression in NK cells and ILC1s is both tissue and cell type specific: the genes induced by the GR pathway in each cellular target are highlighted in green (Down in GR), while the genes repressed by the GR pathway are in red (Up in GR). The GR pathway inhibits IFN‐γ production only in NK cells in the spleen through the induction of PD1 expression. This regulation is required to prevent immunopathology in the spleen, without affecting antiviral response
Figure 2Analysis of the genes regulated by GR in liver ILC1s upon MCMV infection. Transcriptomic data (RNAseq) published in are analyzed (GSE114827).41 The differentially expressed genes (DEGs) between liver ILC1s sorted from MCMV infected Control and GR mice were classified into non‐redundant functional categories by combining gene ontology (GO) analysis and literature‐based manual curation (A). The DEGs involved in immune system processes were analyzed and the heat map in B represents their RNA‐seq expression levels, as measured by reads per kilobase per million reads (RPKM), and asinh scaled. Among these genes, 12 transcripts encode for proteins involved in adhesion and migration of immune cells. With the exception of Ccl22, upregulated in GR deficient ILC1s and whose function has been related to type2 response and migration of T regs, GCs induce all of the genes listed. In particular, in liver ILC1s, GCs induce the upregulation of the genes Amigo3, Nectin4, SelL encoding adhesion molecules, and the genes Itgb5 and Itgam encoding integrins. GCs also upregulate the expression of the genes encoding the chemokines CX3CL1 and CCL9, which attract monocytes, NK cells and neutrophils, respectively
Figure 3Neural pathways innervating the respiratory and intestinal mucosa. The CNS communicates with the lung and intestine through sympathetic, parasympathetic, and sensory neurons. Sympathetic neurons have their cell bodies in the paravertebral ganglia, whereas parasympathetic neurons have their cell bodies in the brainstem and sacral region of the spinal cord (S2‐S4). They project to the organs via the vagus nerve or the pelvic nerve respectively. Afferent sensory innervation involves neurons with cell bodies residing within the DRG (dorsal root ganglia). The lung contains peculiar neuroendocrine cells, the PNECs (pulmonary neuroendocrine cells), which cluster together to form extensive synaptic contacts with afferent and efferent nerve fibers. The intestine is innervated by intrinsic neurons of the ENS (enteric nervous system), which have cell bodies located in the mucosal, submucosal, and myenteric plexuses and communicate with the CNS. The ILCs in the lung and intestine express receptors for the neurotransmitters and neuropeptides released in these tissues: β2‐AR (β2‐adrenergic receptor) for epinephrine and norepinephrine, CHRM (cholinergic receptor muscarinic) for acetylcholine, VPAC1/2 (vasoactive intestinal peptide receptor) for VIP, NMUR1 (NMU receptor) for NMU and CALCRL (calcitonin receptor‐like) for CGRP
Mediators of neuroendocrine pathways and their effects on ILC targets
| Neuro‐endocrine pathway | Experimental model | ILC target | Effect | Reference |
|---|---|---|---|---|
| Glucocorticoids | Endotoxin tolerance | ILC1, NK cells | ↓IFNγ production | Quatrini (2017) |
| Glucocorticoids | MCMV | Spleen NK cells |
| Quatrini (2018) |
| Estrogens | In vitro exposure to E2 | NK cells | ↑ IFNγ production | Nakaya (2006) |
| Estrogens | Ovariectomy and E2 administration | NK cells | ↓ Expression of activating receptors and cytotoxicity | Hao (2007) |
| Progesterone | In vitro migration assay | Human blood NK cells | Reprogramming of chemokine receptor profile | Carlino (2008) |
| Testosterone | IL‐33, | Lung ILC2 | ↓ IL‐15 and IL‐13 production and cell proliferation | Laffont (2017); Cephus (2017) |
| Estrogens, progesterone | Ovariectomy and E2+P4 administration | Uterus ILC2 | Steady state accumulation | Bartemes (2018) |
| GFL | MyoD88‐dependent activation of glial cells | ILC3 in the gut lamina propria | RET‐dependent induction of IL‐22 production | Ibiza (2016) |
| Cholinergic pathway | Stroke | Brain NK cells | ↓ RUNX3 and inhibition of cell response | Liu (2017) |
| Cholinergic pathway | Vagotomy + | ILC3 in the peritoneum | Ach‐induced production of PCTR1 | Dalli (2017) |
| B2adr pathway | Stroke | Spleen NK cells | ↑ SOCS3 and inhibition of cell response | Liu (2017) |
| B2adr pathway | Noradrenergic spleen innervation | Spleen NK cells | Circadian oscillation GrzB and perforin content | Dokur (2004); Logan (2011) |
| B2adr pathway | In vitro stimulation | NK cells | Detachment from the endothelium | Benschop (1993) |
| B2adr pathway | Acute stress (restraint stress) | Lung NK cells | ↓ cell number | Kanemi (2005) |
| B2adr pathway | Chronic stress (social disruption) | Blood NK cells | ↑cell numbers, CD16, CD69, CD107, IFNγ ↓ NKG2A and Ly49A | Tarr (2012) |
| B2adr pathway | Enriched environment | NK cells | ↑ NKG2D and CCR5 expression ↑ infiltration in pancreatic tumor model | Song (2017) |
| B2adr pathway |
| Gut ILC2s | ↓ proliferation and effector functions | Moriyama (2018) |
| B2adr pathway | IL33, | Lung ILC2s | ↓ proliferation and effector functions | Moriyama (2018) |
| VIP | OVA challenge | Lung ILC2s | IL13 production | Talbot (2015) |
| VIP | In vitro VIP + IL7 | Small intestine ILC2s | ↑ IL5 production | Nussbaum (2013) |
| VIP | Circadian/metabolic cues | Lung/small intestine ILC2s | IL‐5‐dependent homeostatic accumulation of eosinophils | Nussbaum (2013) |
| NMU | In vitro stimulation with IL25 | Lung ILC2 | Synergy NMU+IL25 in induction of IL13, IL5 and cell proliferation | Wallrapp (2017) |
| NMU | In vitro stimulation | Small intestine ILC2s | IL13 and IL5 induction comparable to PMA/iono or IL2,7,25,33 combination | Klose (2017) |
| NMU |
| Small intestine ILC2s | ↑ IL13 production and proliferation, with ↑ eosinophilia and worm expulsion | Cardoso (2017) |
| NMU |
| Lung ILC2s | ↑ ILC2 proliferation, maturation and cytokine expression, with ↑ lung inflammation | Klose (2017) |
| CGRP | In vitro stimulation | Lung ILC2s | ↑ IL5 production induced by IL7+25+33 | Sui (2018) |
| CGRP | HDM | Lung ILC2s | ↓ immune cell infiltration in the lung | Sui (2018) |